Computational Assessment of GABA Receptor Modulation in PTSD
A legfontosabb adatok
- Ki végzi
- VA Office of Research and Development
- Hol
- San Diego (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 4. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2025. júl. 1.
- Várható befejezés
- 2029. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Lorazepam 1 mg tablet
- Placebo tablet
- A regiszteradat frissítve
- 2026. június 16.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Veteran
- 18-65 years of age, inclusive
- Participants must be willing to abstain from alcohol 24 hours prior to and 24 hours after the testing session
- Participants must be able to participate and willing to give written informed consent and to comply with the study restrictions; Additional Inclusion Criteria for PTSD Group:; (a) Current diagnosis of PTSD based on CAPS-5
Ki nem vehet részt
- Pregnancy (assessed by urine test at time of screening and prior to administration of study medication) or lactation
- Positive urine toxicology (drugs of abuse as determined by a positive urine test) at screening and before drug administration. Subjects who screen positive for THC will be given an opportunity to be included in the event of a negative urine test 2 weeks later. THC is not infrequently used for medicinal purposes and, in California, is legal for recreational use. Subjects who are positive for THC will therefore not be excluded, but will be retested to ensure that THC is unlikely to be influencing results
- Self-report or observable signs of drug or alcohol intoxication or withdrawal
- Current benzodiazepine or opioid use; other psychotropic medications are allowed as long as they are at a stable dose for at least 2 weeks and do not exhibit an unsafe interaction with the study medication
- Current or recent use of any medication deemed by the study physician (Dr. Howlett) to exhibit an unsafe interaction with lorazepam
- Any other reason why, per study physician, the subject should not participate in this study, including concomitant disease or condition that could interfere with, or for which the study drug might interfere with, the conduct of the study, or that would, in the opinion of the study physician, pose an unacceptable risk to the subject in this study; Additional Exclusion Criteria for HC Group:; (a) Axis I disorder as assessed by MINI; Additional Exclusion Criteria for fMRI Participants:
- Has uncontrolled, clinically significant neurologic (including seizure disorders), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality, which may impact the ability of the subject to participate or potentially confound the study results
- Lifetime history of a chronic psychotic disorder or bipolar disorder type I as assessed by MINI
- Current moderate or severe substance use disorder as assessed by MINI
- Past intolerance (including allergic) to lorazepam or another benzodiazepine
- History of a traumatic brain injury (TBI) resulting in loss of consciousness for more than 30 minutes
- Volunteers who do not have sufficient command of the English language, or who have any other impairment that would prevent them from reading and understanding the informed consent form(s) and completing the study procedures including clinical testing
- Active suicidal ideation or otherwise considered at high suicidal risk by trained study staff using the C-SSRS
- Contraindication to magnetic resonance imaging
- Not right-handed as assessed by Edinburgh Handedness Inventory
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- VA San Diego Healthcare System, San Diego, CASan Diego, Egyesült ÁllamokContact: Vitaliana R Vasquez, BARésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely varies from individual to individual. New scientific tools to help identify distinct subgroups of Veterans with PTSD who are likely to respond to specific medications could help improve treatment in this population. Research has indicated that a specific subgroup of Veterans with PTSD with a high level of anxious arousal may benefit from medications which boost signaling of the neurotransmitter gamma-aminobutyric acid (GABA). This project aims to validate a clinical test to identify these individuals using new computational and neuroimaging methods combined with the medication lorazepam, a positive GABA modulator. The ultimate goal is to use these methods in future clinical trials of new medications to target the best treatments to individual Veterans with PTSD.
A vizsgálat 2 csoportja
- Lorazepam 1 mg, then placeboA vizsgált kezelés
Participants will first receive a single dose of lorazepam 1 mg on the first testing session. After a 1 week washout period, participants will then receive a single dose of placebo on the second testing session.
Kezelés: Lorazepam 1 mg tablet és Placebo tablet
- Placebo, then lorazepam 1 mgA vizsgált kezelés
Participants will first receive a single dose of placebo on the first testing session. After a 1 week washout period, participants will then receive a single dose of lorazepam 1 mg on the second testing session.
Kezelés: Lorazepam 1 mg tablet és Placebo tablet
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Individualized Computational Assessment of the Effects of GABA Receptor Modulation in Posttraumatic Stress Disorder
- Kérdések a feltételekről
- Forrás: NCT06852469: ki vehet részt
- A regiszteradat frissítve
- 2026. június 16.